Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder
C. Okhuijsen-Pfeifer, M.Z. van der Horst, C.A. Bousman, B. Lin, K.R. van Eijk, S. Ripke, Y. Ayhan, M.O. Babaoglu, M. Bak, W. Alink, H. van Beek, E. Beld, A. Bouhuis, M. Edlinger, I.M. Erdogan, A. Ertuğrul, G. Yoca, I.P. Everall, T. Görlitz, GROUP Genetic Risk and Outcome of Psychosis investigators, K.P. Grootens, S. Gutwinski, T. Hallikainen, E. Jeger-Land, M. de Koning, M. Lähteenvuo, S.E. Legge, S. Leucht, C. Morgenroth, A. Müderrisoğlu, A. Narang, C. Pantelis, A.F. Pardiñas, T. Oviedo-Salcedo, J. Schneider-Thoma, S. Schreiter, E. Repo-Tiihonen, H. Tuppurainen, M. Veereschild, S. Veerman, M. de Vos, E. Wagner, D. Cohen, J.P.A.M. Bogers, J.T.R. Walters, A.E. Anil Yağcıoğlu, J. Tiihonen, A. Hasan, J.J. Luykx
medRxiv 2021.06.06.21258200; doi: https://doi.org/10.1101/2021.06.06.21258200